Paul D. Eve

774 total citations
9 papers, 326 citations indexed

About

Paul D. Eve is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Paul D. Eve has authored 9 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Oncology and 2 papers in Cell Biology. Recurrent topics in Paul D. Eve's work include Cancer-related Molecular Pathways (5 papers), DNA Repair Mechanisms (4 papers) and Microtubule and mitosis dynamics (2 papers). Paul D. Eve is often cited by papers focused on Cancer-related Molecular Pathways (5 papers), DNA Repair Mechanisms (4 papers) and Microtubule and mitosis dynamics (2 papers). Paul D. Eve collaborates with scholars based in United Kingdom, United States and Canada. Paul D. Eve's co-authors include Michelle D. Garrett, Ian Collins, Michael I. Walton, Florence I. Raynaud, Suzanne A. Eccles, Melanie Valenti, Wynne Aherne, John Caldwell, Gary Box and John Reader and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Paul D. Eve

8 papers receiving 321 citations

Peers

Paul D. Eve

MB

ONCOL

CB

CR

GENET

Charina Ortega United States

Shannon Ready United Kingdom

Kenna Anderes United States

Hélène Malka-Mahieu France

Tatiana Erazo Spain

Emma J. Haagensen United Kingdom

Calvo Medina United States

Ruth E. Feltell United Kingdom

Yu-Gang Song China

Mamatha Reddy United States

Charina Ortega United States

Paul D. Eve

220 ×0.8

MB

71 ×0.5

ONCOL

23 ×0.5

CB

31 ×0.8

CR

29 ×1.2

GENET

Citations per year, relative to Paul D. Eve Paul D. Eve (= 1×) peers Charina Ortega

Countries citing papers authored by Paul D. Eve

Since Specialization

Citations

This map shows the geographic impact of Paul D. Eve's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul D. Eve with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul D. Eve more than expected).

Fields of papers citing papers by Paul D. Eve

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul D. Eve. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul D. Eve. The network helps show where Paul D. Eve may publish in the future.

Co-authorship network of co-authors of Paul D. Eve

This figure shows the co-authorship network connecting the top 25 collaborators of Paul D. Eve. A scholar is included among the top collaborators of Paul D. Eve based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul D. Eve. Paul D. Eve is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Walters, Zoë S., Ewa Aładowicz, Joanna Selfe, et al.. (2021). Role for the Histone Demethylase KDM4B in Rhabdomyosarcoma via CDK6 and CCNA2: Compensation by KDM4A and Apoptotic Response of Targeting Both KDM4B and KDM4A. Cancers. 13(7). 1734–1734. 6 indexed citations

2.

Walton, Mike I., Paul D. Eve, Angela Hayes, et al.. (2012). CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs. Clinical Cancer Research. 18(20). 5650–5661. 69 indexed citations

3.

Lainchbury, Michael, Thomas P. Matthews, Tatiana McHardy, et al.. (2012). Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors. Journal of Medicinal Chemistry. 55(22). 10229–10240. 22 indexed citations

4.

Anderson, Victoria E., Michael I. Walton, Paul D. Eve, et al.. (2011). CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors. Cancer Research. 71(2). 463–472. 79 indexed citations

5.

Yap, Timothy A., Mike I. Walton, Melanie Valenti, et al.. (2010). Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930. Molecular Cancer Therapeutics. 10(2). 360–371. 59 indexed citations

6.

Walton, Michael I., Paul D. Eve, Angela Hayes, et al.. (2010). The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106. Molecular Cancer Therapeutics. 9(1). 89–100. 63 indexed citations

7.

Martin, Nicholas G., Craig McAndrew, Paul D. Eve, & Michelle D. Garrett. (2008). Phosphorylation of cyclin dependent kinase 4 on tyrosine 17 is mediated by Src family kinases. FEBS Journal. 275(12). 3099–3109. 7 indexed citations

8.

Sellick, Gabrielle S., Matthew Rudd, Paul D. Eve, et al.. (2004). The P2X7 Receptor Gene A1513C Polymorphism Does Not Contribute to Risk of Familial or Sporadic Chronic Lymphocytic Leukemia. Cancer Epidemiology Biomarkers & Prevention. 13(6). 1065–1067. 21 indexed citations

9.

Eve, Paul D.. (1973). Cooking with rice. Medical Entomology and Zoology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact